Sorrento Therapeutics Subsidiary, Scilex, Receives FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for Post-Herpetic Neuralgia Pain

FDA News, New FDA Approvals
February 28, 2018
A+ A-
Email Print

Article Link: Sorrento Therapeutics Subsidiary, Scilex, Receives FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for Post-Herpetic Neuralgia Pain

SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ:SRNE) (“Sorrento”), and its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”), received approval from the U.S. Food and Drug Administration…

Source: FDA New Drug Approvals

Posted by

Newer Post
Older Post